Key clinical point: Polatuzumab vedotin plus rituximab or obinutuzumab, in addition to cyclophosphamide, doxorubicin, and prednisone, showed manageable safety and positive clinical outcomes in patients with previously untreated diffuse large B-cell lymphoma.
Major finding: At a median follow-up of 21.5 months, the overall response rate was 89% in study participants, including 77% of patients who achieved a complete response and 12% who had a partial response.
Study details: A phase 1b/2 study of 85 patients with previously untreated diffuse large B-cell lymphoma.
Disclosures: The study was funded by F. Hoffmann-La Roche and Genentech. The authors reported financial affiliations with AstraZeneca, Bristol-Myers Squibb, Celgene, Gilead, Janssen, Merck, Pfizer, and others.
Tilly H et al. Lancet Oncol. 2019 May 14. doi: 10.1016/S1470-2045(19)30091-9.